Table 1.

Baseline characteristics of randomized controlled trials included in the meta-analysis

Author	Year	Trial design	Jadad scale	Malignancy	Treatment arm	Sample size	Median age (range), years	Treatment duration, median (range)	ECOG PS 0–1 (%)	NCI-CTCAE version
Grothey et al3	2013	III	5	Metastatic CRC	Regorafenib	505	61 (54–67)	1.7 months (1.4–3.7)	100	3.0
					Placebo	255	61 (54–68)	1.6 months (1.3–1.7)
Demetri et al4	2013	III	5	Advanced GIST	Regorafenib	133	60 (51–67)	22.9 weeks (9.3–28.6)	100	4.0
					Placebo	66	61 (48–66)	7.0 weeks (5.1–11.3)
Li et al6	2015	III	5	Metastatic CRC	Regorafenib	136	57.5 (50–66)	2.4 months (1.6–5.3)	100	4.0
					Placebo	68	55.5 (48.5–62)	1.6 months (1.1–1.6)
Bruix et al5	2017	III	5	Advanced HCC	Regorafenib	379	64 (54–71)	3.6 months (1.6–7.6)	100	4.03
					Placebo	194	62 (55–68)	1.9 months (1.4–3.9)
Pavlakis et al8	2016	II	5	Advanced GC	Regorafenib	97	63 (33–81)	1.8 months (1.4–2.0)	100	4.0
					Placebo	50	62 (32–85)	0.9 months (0.9–1.0)
Mir et al7	2016	II	5	Advanced liposarcoma	Regorafenib	20	57 (24–76)	1.6 months (0.7–2.4)	98	4.03
					Placebo	23	65 (22–80)	1.9 months (1.6–4.8)
				Advanced leiomyosarcoma	Regorafenib	28	60 (37–74)	3.9 months (2.0–8.7)	100
					Placebo	28	60 (30–76)	2.3 months (1.6–4.6)
				Advanced synovial sarcomas	Regorafenib	13	46 (21–73)	3.4 months (0.7–6.7)	100
					Placebo	14	35 (20–78)	1.4 months (0.7–2.0)
				Other advanced sarcomas	Regorafenib	29	60 (26–81)	3.5 months (0.6–10.2)	100
					Placebo	27	55 (20–78)	2.8 months (1.1–5.1)

Abbreviations: CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; GC, gastric cancer; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events.